Characterization of intraocular pressure increases and management strategies following treatment with fluocinolone acetonide intravitreal implants in the fame trials

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 47, Issue 5, 2016, Pages 426-435

  Parrish, Richard K ^a   Campochiaro, Peter A ^b   Pearson, P Andrew ^c   Green, Ken ^d   Traverso, Carlo E ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Alimera Sciences Limited   (United States)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUOCINOLONE ACETONIDE; OSMOTIC AGENT; PROSTAGLANDIN; ANTIHYPERTENSIVE AGENT; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; ARTICLE; BEST CORRECTED VISUAL ACUITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DRUG DOSE COMPARISON; DRUG EXPOSURE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TONOMETRY; TRABECULOPLASTY; TREATMENT OUTCOME; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DISEASE MANAGEMENT; DOSE RESPONSE; DRUG EFFECTS; DRUG IMPLANT; FOLLOW UP; MACULAR EDEMA; MULTICENTER STUDY; OCULAR HYPERTENSION; OCULOPLETHYSMOGRAPHY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; PRACTICE GUIDELINE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TRABECULECTOMY; VISUAL ACUITY; VITREOUS BODY;

ANTIHYPERTENSIVE AGENTS; DIABETIC RETINOPATHY; DISEASE MANAGEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MIDDLE AGED; OCULAR HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; TIME FACTORS; TONOMETRY, OCULAR; TRABECULECTOMY; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 84983439216     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20160419-05     Document Type: Article

References (23)

1. Lucentis (ranibizumab injection) [package insert]. South San Francisco, CA: Genentech; 2014.
2. Eylea (aflibercept injection) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; 2014.
3. Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375-381.
4. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: The 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013-2022.
5. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247-2254.
6. Bressler SB, Qin H, Beck RW, et al. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130(9):1153-1161.
7. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentra-tions of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152(4):686-694.
8. Dong N, Xu B, Chu L, Tang X. Study of 27 aqueous humor cytokines in type 2 diabetic patients with or without macular edema. PLoS One. 2015;10(4):e0125329.
9. Boyer DS, Yoon YH, Belfort R Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
10. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-635.e2.
11. Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-2132.
12. Ozurdex (dexamethasone intravitreal implant) [package insert]. Irvine, CA: Allergan; 2014.
13. Iluvien (fluocinolone acetonide intravitreal implant) [package insert]. Alpharetta, GA: Alimera Sciences; 2014.
14. Schwartz SG, Flynn HW Jr., Scott IU. Intravitreal corticosteroids in the management of diabetic macular edema. Curr Ophthalmol Rep. 2013;1(3). doi:10.1007/s40135-013-0015-3.
15. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447-9, 1449.e1-10.
16. James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23(5):403-420.
17. Jones R III, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: A brief review and update of the literature. Curr Opin Ophthalmol. 2006;17(2):163-167.
18. Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47(2):66-80.
19. Mozaffarieh M, Grieshaber MC, Flammer J. Oxygen and blood flow: Players in the pathogenesis of glaucoma. Mol Vis. 2008;14:224-233.
20. Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for openangle glaucoma (UKGTS): A randomised, multicentre, placebocontrolled trial. Lancet. 2015;385(9975):1295-1304.
21. Peden MC, Suner IJ, Hammer ME, Grizzard WS. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. Ophthalmology. 2015;122(4):803-808.
22. Hollands H, Seif G, Hollands S, Gale J. A trial of topical prednisolone acetate before intravitreal triamcinolone acetonide decreases intraocular pressure spikes. Can J Ophthalmol. 2010;45(5):484-488.
23. Nehme A, Lobenhofer EK, Stamer WD, Edelman JL. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics. 2009;2:58. doi: 10.1186/1755-8794-2-58.